362 related articles for article (PubMed ID: 33563578)
21. Multiregional single-cell proteogenomic analysis of ccRCC reveals cytokine drivers of intratumor spatial heterogeneity.
Miheecheva N; Postovalova E; Lyu Y; Ramachandran A; Bagaev A; Svekolkin V; Galkin I; Zyrin V; Maximov V; Lozinsky Y; Isaev S; Ovcharov P; Shamsutdinova D; Cheng EH; Nomie K; Brown JH; Tsiper M; Ataullakhanov R; Fowler N; Hsieh JJ
Cell Rep; 2022 Aug; 40(7):111180. PubMed ID: 35977503
[TBL] [Abstract][Full Text] [Related]
22. Breast cancer intratumor genetic heterogeneity: causes and implications.
Ng CK; Pemberton HN; Reis-Filho JS
Expert Rev Anticancer Ther; 2012 Aug; 12(8):1021-32. PubMed ID: 23030222
[TBL] [Abstract][Full Text] [Related]
23. Microfluidic design in single-cell sequencing and application to cancer precision medicine.
Han X; Xu X; Yang C; Liu G
Cell Rep Methods; 2023 Sep; 3(9):100591. PubMed ID: 37725985
[TBL] [Abstract][Full Text] [Related]
24. Evolutionary Mechanisms of Cancer Suggest Rational Therapeutic Approaches.
Balzerano A; Paccosi E; Proietti-De-Santis L
Cytogenet Genome Res; 2021; 161(6-7):362-371. PubMed ID: 34461614
[TBL] [Abstract][Full Text] [Related]
25. Intratumor Heterogeneity in Breast Cancer.
Beca F; Polyak K
Adv Exp Med Biol; 2016; 882():169-89. PubMed ID: 26987535
[TBL] [Abstract][Full Text] [Related]
26. Tumour heterogeneity and resistance to cancer therapies.
Dagogo-Jack I; Shaw AT
Nat Rev Clin Oncol; 2018 Feb; 15(2):81-94. PubMed ID: 29115304
[TBL] [Abstract][Full Text] [Related]
27. Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes.
Dentro SC; Leshchiner I; Haase K; Tarabichi M; Wintersinger J; Deshwar AG; Yu K; Rubanova Y; Macintyre G; Demeulemeester J; Vázquez-García I; Kleinheinz K; Livitz DG; Malikic S; Donmez N; Sengupta S; Anur P; Jolly C; Cmero M; Rosebrock D; Schumacher SE; Fan Y; Fittall M; Drews RM; Yao X; Watkins TBK; Lee J; Schlesner M; Zhu H; Adams DJ; McGranahan N; Swanton C; Getz G; Boutros PC; Imielinski M; Beroukhim R; Sahinalp SC; Ji Y; Peifer M; Martincorena I; Markowetz F; Mustonen V; Yuan K; Gerstung M; Spellman PT; Wang W; Morris QD; Wedge DC; Van Loo P;
Cell; 2021 Apr; 184(8):2239-2254.e39. PubMed ID: 33831375
[TBL] [Abstract][Full Text] [Related]
28. Integrative insights and clinical applications of single-cell sequencing in cancer immunotherapy.
Liu Z; Li H; Dang Q; Weng S; Duo M; Lv J; Han X
Cell Mol Life Sci; 2022 Oct; 79(11):577. PubMed ID: 36316529
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy guided precision medicine in solid tumors.
Mehrotra S; Kupani M; Kaur J; Kaur J; Pandey RK
Adv Protein Chem Struct Biol; 2024; 140():249-292. PubMed ID: 38762271
[TBL] [Abstract][Full Text] [Related]
30. Tumor Functional Heterogeneity Unraveled by scRNA-seq Technologies.
González-Silva L; Quevedo L; Varela I
Trends Cancer; 2020 Jan; 6(1):13-19. PubMed ID: 31952776
[TBL] [Abstract][Full Text] [Related]
31. Intratumor Heterogeneity and Antitumor Immunity Shape One Another Bidirectionally.
Wolf Y; Samuels Y
Clin Cancer Res; 2022 Jul; 28(14):2994-3001. PubMed ID: 35380639
[TBL] [Abstract][Full Text] [Related]
32. Precision Oncology Beyond Genomics: The Future Is Here-It Is Just Not Evenly Distributed.
Pfohl U; Pflaume A; Regenbrecht M; Finkler S; Graf Adelmann Q; Reinhard C; Regenbrecht CRA; Wedeken L
Cells; 2021 Apr; 10(4):. PubMed ID: 33920536
[TBL] [Abstract][Full Text] [Related]
33. DITHER: an algorithm for Defining IntraTumor Heterogeneity based on EntRopy.
Li L; Chen C; Wang X
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34096997
[TBL] [Abstract][Full Text] [Related]
34. Deciphering intratumor heterogeneity using cancer genome analysis.
Ryu D; Joung JG; Kim NK; Kim KT; Park WY
Hum Genet; 2016 Jun; 135(6):635-42. PubMed ID: 27126234
[TBL] [Abstract][Full Text] [Related]
35. Tumour heterogeneity and the evolution of polyclonal drug resistance.
Burrell RA; Swanton C
Mol Oncol; 2014 Sep; 8(6):1095-111. PubMed ID: 25087573
[TBL] [Abstract][Full Text] [Related]
36. Artificial Intelligence in Bulk and Single-Cell RNA-Sequencing Data to Foster Precision Oncology.
Del Giudice M; Peirone S; Perrone S; Priante F; Varese F; Tirtei E; Fagioli F; Cereda M
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925407
[TBL] [Abstract][Full Text] [Related]
37. Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come?
El-Deiry WS; Taylor B; Neal JW
Am Soc Clin Oncol Educ Book; 2017; 37():e8-e15. PubMed ID: 28746017
[TBL] [Abstract][Full Text] [Related]
38. Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer.
Hsieh JJ; Manley BJ; Khan N; Gao J; Carlo MI; Cheng EH
Semin Cell Dev Biol; 2017 Apr; 64():98-106. PubMed ID: 27615548
[TBL] [Abstract][Full Text] [Related]
39. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine.
Ogino S; Fuchs CS; Giovannucci E
Expert Rev Mol Diagn; 2012 Jul; 12(6):621-8. PubMed ID: 22845482
[TBL] [Abstract][Full Text] [Related]
40. Engineering Multidimensional Evolutionary Forces to Combat Cancer.
McCoach CE; Bivona TG
Cancer Discov; 2019 May; 9(5):587-604. PubMed ID: 30992280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
